The effect of combining PARP inhibitors with modulation of PRMT5 or Type I PRMTs, responsible for the production of ADMA, has been observed in AML and NSCLC models, respectively [refs. 70, 71]. This evidence concerns the gene PRMT5 and acute myeloid leukemia.